LYEL

Lyell Immunopharma, Inc.

LYEL · CIK 1806952 · Annual (10-K) · Last 4 years

Financial Trends

Revenue$0M
20212024
Net Income−$343M
20212024
Operating CF−$162M
20212024
Free Cash Flow−$163M
20212024

Income Statement

MetricFY 2024FY 2023FY 2022FY 2021
Revenue$0.0B$0.0B$0.1B$0.0B
Cost of Revenue
Gross Profit
R&D Expense$0.2B$0.2B$0.1B
SG&A Expense
Operating Income$-0.4B$-0.2B$-0.2B$-0.2B
Net Income$-0.3B$-0.2B$-0.2B$-0.3B
EPS (Basic)$-1.31$-0.93$-0.74$-1.84
EPS (Diluted)$-1.31$-0.93$-0.74$-1.84

Balance Sheet

MetricFY 2024FY 2023FY 2022FY 2021
Total Assets$0.5B$0.8B$0.9B$1.1B
Current Assets$0.4B$0.6B$0.7B$0.6B
Cash & Equivalents$0.1B$0.1B$0.1B$0.3B
Total Liabilities$0.1B$0.1B$0.1B$0.2B
Current Liabilities$0.1B$0.0B$0.0B$0.0B
Stockholders' Equity$0.4B$0.7B$0.8B$0.9B

Cash Flow Statement

MetricFY 2024FY 2023FY 2022FY 2021
Operating Cash Flow$-0.2B$-0.2B$-0.2B$-0.1B
Investing Cash Flow$0.1B$0.2B$-0.0B$-0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.1B
Financing Cash Flow$0.0B$0.0B$0.0B$0.4B